Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan Maintenance in Healed Erosive Esophagitis
NCT02388737Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan in erosive esophagitis (EE) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase. Started Apr 2015; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT02388737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388737.